HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

HCW Biologics requested a Type B pre-IND meeting with the FDA to discuss the regulatory strategy for its lead candidate HCW11-018b, a tetravalent T-cell engager targeting solid tumors. The company remains on track to initiate clinical trials for the program in the first half of 2027, supported by preclinical data indicating efficacy in gynecologic and pancreatic cancers.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.